Mesenchymal stem cell transplantation in multiple sclerosis.

Mesenchymal stem cell transplantation in multiple sclerosis.
复制标题

DOI:
10.1016/j.jns.2012.12.009
复制
发表时间:
2013-10-15
影响因子:
4.4
通讯作者:
Cohen, Jeffrey A.
Cohen, Jeffrey A.
中科院分区:
医学3区
文献类型:
--
作者:
Cohen, Jeffrey A.

文献摘要

参考文献

被引文献

相似文献

间充质干细胞(Mesenchymal stem cells,MSCs)是一种多能性非造血前体细胞,可从骨髓和许多其他组织中分离、培养扩增至纯度,并在体外和体内诱导分化为中胚层衍生物。MSC表现出许多表型和功能相似的周细胞。在体外和动物模型中证明的MSC的免疫调节、组织保护和促进修复特性使其成为MS和以炎症和/或组织损伤为特征的其他病症的有吸引力的潜在疗法。MSC作为治疗剂的其他潜在优势包括培养扩增的相对容易性、允许同种异体移植的相对免疫特权以及它们从血液运输到允许血管内施用的组织区域的能力。MSC移植在MS中的总体发表经验是适度的,但几个小的病例系列和初步研究产生了有希望的结果。包括我们在内的几个小组最近开始了MS自体、培养扩增、骨髓源性MSC移植的正式研究。尽管存在一些潜在的安全性问题,但迄今为止,该程序耐受性良好。未来更明确评估疗效的研究还需要解决几个技术问题。
Mesenchymal stem cells (MSCs) are a pluripotent non-hematopoietic precursor cells that can be isolated from bone marrow and numerous other tissues, culture-expanded to purity, and induced to differentiate in vitro and in vivo into mesodermal derivatives. MSCs exhibit many phenotypic and functional similarities to pericytes. The immunomodulatory, tissue protective, and repair-promoting properties of MSCs demonstrated both in vitro and in animal models make them an attractive potential therapy for MS and other conditions characterized by inflammation and/or tissue injury. Other potential advantages of MSCs as a therapeutic include the relative ease of culture expansion, relative immunoprivilege allowing allogeneic transplantation, and their ability to traffic from blood to areas of tissue allowing intravascular administration. The overall published experience with MSC transplantation in MS is modest, but several small case series and preliminary studies yielded promising results. Several groups, including us, recently initiated formal studies of autologous, culture-expanded, bone-marrow-derived MSC transplantation in MS. Although there are several potential safety concerns, to date, the procedure has been well tolerated. Future studies that more definitively assess efficacy also will need to address several technical issues.
DOI: 10.1016/s1474-4422(11)70305-2
发表时间: 2012-02
期刊: LANCET NEUROLOGY
影响因子: 48
作者:
Connick, Peter;Kolappan, Madhan;Crawley, Charles;Webber, Daniel J.;Patani, Rickie;Michell, Andrew W.;Du, Ming-Qing;Luan, Shi-Lu;Altmann, Daniel R.;Thompson, Alan J.;Compston, Alastair;Scott, Michael A.;Miller, David H.;Chandran, Siddharthan
通讯作者: Chandran, Siddharthan
DOI: 10.1016/s0301-472x(01)00769-x
发表时间: 2002-01-01
影响因子: 2.6
作者:
Bartholomew, A;Sturgeon, C;Hoffman, R
通讯作者: Hoffman, R
DOI: 10.1161/01.str.0000247888.25985.62
发表时间: 2007-02-01
期刊: STROKE
影响因子: 8.3
作者:
Bliss, Tonya;Guzman, Raphael;Steinberg, Gary K.
通讯作者: Steinberg, Gary K.
DOI: 10.1016/j.ejcb.2009.02.001
发表时间: 2009-06-01
影响因子: 6.6
作者:
Danielyan, Lusine;Schaefer, Richard;Frey, William H., II
通讯作者: Frey, William H., II
DOI: 10.1016/s0301-472x(00)00635-4
发表时间: 2001-02-01
影响因子: 2.6
作者:
Devine, SM;Bartholomew, AM;Hoffman, R
通讯作者: Hoffman, R